Edesa Biotech Past Earnings Performance
Past criteria checks 0/6
Edesa Biotech's earnings have been declining at an average annual rate of -8.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 83% per year.
Key information
-8.1%
Earnings growth rate
10.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -83.0% |
| Return on equity | -311.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely
Aug 04
We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate
Mar 10Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%
Sep 30Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Sep 23Edesa says mid-stage trial for anti-allergic cream reached full enrollment
Sep 07Edesa Biotech GAAP EPS of -$0.37 beats by $0.06
Aug 12Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth
May 16Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD
Apr 18Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Dec 08Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
Sep 22Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Aug 27Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study
Jun 18Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?
Apr 13Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)
Feb 19Edesa Biotech receives C$14M for COVID-19 study
Feb 02Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Dec 08
Edesa Biotech EPS misses by $0.04, beats on revenue
Dec 07Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment
Nov 03Revenue & Expenses Breakdown
How Edesa Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -6 | 4 | 3 |
| 30 Jun 24 | 0 | -7 | 5 | 4 |
| 31 Mar 24 | 0 | -7 | 5 | 4 |
| 31 Dec 23 | 0 | -8 | 5 | 4 |
| 30 Sep 23 | 0 | -8 | 4 | 5 |
| 30 Jun 23 | 0 | -9 | 4 | 6 |
| 31 Mar 23 | 0 | -13 | 4 | 9 |
| 31 Dec 22 | 0 | -16 | 5 | 11 |
| 30 Sep 22 | 0 | -18 | 5 | 13 |
| 30 Jun 22 | 0 | -18 | 5 | 16 |
| 31 Mar 22 | 0 | -17 | 6 | 16 |
| 31 Dec 21 | 0 | -15 | 6 | 21 |
| 30 Sep 21 | 0 | -13 | 6 | 18 |
| 30 Jun 21 | 0 | -12 | 5 | 15 |
| 31 Mar 21 | 0 | -9 | 4 | 12 |
| 31 Dec 20 | 0 | -8 | 4 | 4 |
| 30 Sep 20 | 0 | -6 | 3 | 3 |
| 30 Jun 20 | 1 | -5 | 3 | 3 |
| 31 Mar 20 | 1 | -5 | 3 | 2 |
| 31 Dec 19 | 1 | -4 | 3 | 2 |
| 30 Sep 19 | 0 | -3 | 2 | 1 |
| 30 Jun 19 | 0 | -3 | 2 | 1 |
| 31 Mar 19 | 0 | -2 | 1 | 1 |
| 31 Dec 18 | 0 | -2 | 1 | 1 |
Quality Earnings: EDSA is currently unprofitable.
Growing Profit Margin: EDSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EDSA is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare EDSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: EDSA has a negative Return on Equity (-311.44%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 15:53 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Edesa Biotech, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vernon Bernardino | H.C. Wainwright & Co. |
| David Bautz | Zacks Small-Cap Research |